Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment

Journal of Neuroimmunology
P K MaitiSara Fuchs

Abstract

A syngeneic rat recombinant fragment of the extracellular domain of the acetylcholine receptor (AChR) alpha-subunit (Ralpha1-205), administered orally, suppresses ongoing experimental autoimmune myasthenia gravis (EAMG) in rats. The underlying mechanism is a shift from Th1 to Th2 regulation as evidenced by downregulated mRNA expression levels of IFN-gamma and TNF-alpha, upregulated IL-10, changes in anti-AChR IgG isotypes and diminished Th1 signaling via CD28/CTLA-4:B7. Unlike the xenogeneic fragment, the syngeneic Ralpha1-205 does not induce elevation in TGF-beta and elicitation of autoregulatory cells. The ability to suppress EAMG by a non-immunogenic syngeneic fragment of AChR is encouraging and may in the future be applied for the treatment of myasthenia gravis in humans.

References

Jan 1, 1994·European Journal of Immunology·M K KennedyK H Grabstein
Aug 26, 1994·Science·B K FinckD Wofsy
Aug 1, 1994·Immunity·T L WalunasJ A Bluestone
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·K GerritseE Claassen
Aug 1, 1996·The Journal of Clinical Investigation·M KoshyM K Crow
Jan 1, 1996·Annual Review of Immunology·D J LenschowJ A Bluestone
Aug 1, 1996·The Journal of Experimental Medicine·N J KarandikarJ A Bluestone
Mar 11, 2000·The Journal of Clinical Investigation·J ReynoldsC D Pusey
Jun 8, 2000·Muscle & Nerve·N TeleshovaH Link
Oct 20, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S H ImS Fuchs

❮ Previous
Next ❯

Citations

Aug 31, 2012·Clinical and Vaccine Immunology : CVI·Katja GoldmannBernd M Spriewald
Aug 17, 2011·Therapeutics and Clinical Risk Management·Sivakumar Sathasivam
Jul 16, 2005·Expert Opinion on Biological Therapy·Sonia Berrih-AkninMiriam C Souroujon
Oct 23, 2015·Journal of Autoimmunity·Revital ArichaMiriam C Souroujon
Jul 23, 2015·Journal of Neuroimmunology·Ning BuHong-Wei Ren
Jan 5, 2011·Journal of Autoimmunity·Revital ArichaMiriam C Souroujon
Jul 27, 2007·The FEBS Journal·Dimitra KalamidaSocrates J Tzartos
May 4, 2010·Annals of Neurology·Jie LuoJon M Lindstrom
May 4, 2010·Annals of Neurology·Hartmut Wekerle, Reinhard Hohlfeld
Jun 30, 2004·Journal of Neuroimmunology·Andrew R Pachner
Jul 29, 2015·Biochemical Pharmacology·Jie Luo, Jon Lindstrom
Mar 20, 2010·Autoimmunity·M C SouroujonS Fuchs
Feb 20, 2010·Autoimmunity·Donald B Sanders, Amelia Evoli
Jul 18, 2008·Handbook of Clinical Neurology·Daniel B Drachman
Aug 25, 2005·Expert Review of Vaccines·Sylvia Cohen-Kaminsky, Florence Jambou
Mar 17, 2007·Journal of the History of the Neurosciences·Onno G Meijer, Sjoerd M Bruijn
Mar 11, 2009·Expert Review of Neurotherapeutics·Nils Erik Gilhus
Dec 21, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Revital ArichaSara Fuchs
Oct 8, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jie Luo, Jon Lindstrom
Apr 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tali FefermanMiriam C Souroujon
Feb 6, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Revital ArichaMiriam C Souroujon
Dec 18, 2020·Frontiers in Neurology·Konstantinos Lazaridis, Socrates J Tzartos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

© 2022 Meta ULC. All rights reserved